Guaranteed adherence.
Better outcomes.™

Through miniaturized, long-term biopharmaceutical implants, we seek to free patients from medication adherence challenges, minimizing the burden and maximizing the benefit of clinical treatments.

Addressing the biggest challenges in chronic disease treatment – medication non-adherence and tolerability.

An alarming percentage of patients suffering from chronic illnesses don’t take their medications as prescribed, often due to the inconveniences associated with drug administration and/or tolerability, which may be associated with fluctuating drug levels.

Hear from our CEO, Dr. Adam Mendelsohn, on our revolutionary approach to challenges associated with patient behavior.
69%

Of patients do not adhere to their medication due to forgetfulness and inertia.

Our long-term solution for life-long conditions.

At Vivani we are developing our novel NanoPortal™ implant technology for delivering the intended dose of medication steadily over extended periods of time. It has been engineered with the goal of avoiding challenges that may be associated with fluctuating drug delivery.

Our Lead Drug Candidate: NPM-115

GLP-1 for Obesity and Chronic Weight Management

NPM-115 is a miniature, six-month, subdermal, high-dose exenatide drug implant under development for chronic weight management in patients who are obese or overweight. This implant can be conveniently inserted under the skin during a quick outpatient procedure and is designed to provide steady doses of medication for up to six months. Our First-in-Human study, also known as LIBERATE-1 and supportive of NPM-115, is designed to study our exenatide implant in obese and overweight individuals.

Also Developing Candidate: NPM-119

GLP-1 for Type 2 Diabetes

NPM-119 is a miniature, six-month, subdermal, exenatide drug implant under development to treat patients with type 2 diabetes. This device can also be conveniently inserted under the skin during a quick outpatient procedure and is designed to provide steady doses of medication for up to six months.

News & Updates

10.22.24
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD)…

 Read More  

09.26.24
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial…

 Read More  

09.23.24
Vivani Medical to Present at the Emerging Growth Conference on September 25,…

 Read More  

09.04.24
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting…

 Read More  

08.28.24
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment…

 Read More  

08.13.24
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results

 Read More  

07.11.24
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1…

 Read More  

06.13.24
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical…

 Read More  

05.28.24
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary…

 Read More  

05.13.24
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results

 Read More  

< >

Current Disease Targets of NanoPortal Platform Technology

Obesity

Type 2 Diabetes

Feline
Pre-Diabetes & Diabetes